Penbrook Management’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $11.8M | Sell |
311,500
-4,700
| -1% | -$217K | 6.97% | 3 |
|
|
2026
Q2 | $15.2M | Hold |
316,200
| – | – | 9.67% | 1 |
|
|
2026
Q1 | $11.6M | Sell |
316,200
-200
| -0.1% | -$9.48K | 8.8% | 1 |
|
|
2025
Q4 | $16.1M | Buy |
316,400
+4,800
| +2% | +$245K | 11.1% | 1 |
|
|
2025
Q3 | $17.3M | Buy |
311,600
+200
| +0.1% | +$11.7K | 12.07% | 1 |
|
|
2025
Q2 | $21.5M | Hold |
311,400
| – | – | 16.16% | 1 |
|
|
2025
Q1 | $21.6M | Sell |
311,400
-1,000
| -0.3% | -$82.6K | 16.34% | 1 |
|
|
2024
Q4 | $26.9M | Sell |
312,400
-100
| -0% | -$10.8K | 18.33% | 1 |
|
|
2024
Q3 | $37.2M | Sell |
312,500
-100
| -0% | -$13.3K | 24.19% | 1 |
|
|
2024
Q2 | $44.6M | Hold |
312,600
| – | – | 27.24% | 1 |
|
|
2024
Q1 | $40.1M | Sell |
312,600
-600
| -0.2% | -$71.4K | 24.88% | 1 |
|
|
2023
Q4 | $32.4M | Sell |
313,200
-4,000
| -1% | -$396K | 21.77% | 1 |
|
|
2023
Q3 | $28.8M | Hold |
317,200
| – | – | 21.14% | 1 |
|
|
2023
Q2 | $25.7M | Sell |
317,200
-1,200
| -0.4% | -$98K | 18.6% | 1 |
|
|
2023
Q1 | $25.3M | Sell |
318,400
-1,800
| -0.6% | -$128K | 19.41% | 1 |
|
|
2022
Q4 | $21.7M | Sell |
320,200
-22,100
| -6% | -$1.3M | 18.47% | 1 |
|
|
2022
Q3 | $17.1M | Sell |
342,300
-1,000
| -0.3% | -$53.6K | 14.68% | 1 |
|
|
2022
Q2 | $19.1M | Hold |
343,300
| – | – | 15.08% | 1 |
|
|
2022
Q1 | $19.1M | Hold |
343,300
| – | – | 12.37% | 1 |
|
|
2021
Q4 | $19.2M | Hold |
343,300
| – | – | 11.58% | 1 |
|
|
2021
Q3 | $16.5M | Sell |
343,300
-600
| -0.2% | -$29K | 10.24% | 1 |
|
|
2021
Q2 | $14.4M | Hold |
343,900
| – | – | 8.63% | 1 |
|
|
2021
Q1 | $11.6M | Buy |
343,900
+200
| +0.1% | +$7.12K | 8.34% | 1 |
|
|
2020
Q4 | $12M | Buy |
343,700
+90,000
| +35% | +$3.11M | 9.25% | 1 |
|
|
2020
Q3 | $8.81M | Buy |
253,700
+1,000
| +0.4% | +$33.3K | 7.63% | 2 |
|
|
2020
Q2 | $8.27M | Hold |
252,700
| – | – | 8.14% | 2 |
|
|
2020
Q1 | $7.61M | Sell |
252,700
-1,000
| -0.4% | -$29.8K | 9.74% | 1 |
|
|
2019
Q4 | $7.34M | Hold |
253,700
| – | – | 7.15% | 1 |
|
|
2019
Q3 | $6.56M | Sell |
253,700
-400
| -0.2% | -$10.1K | 7.12% | 1 |
|
|
2019
Q2 | $6.48M | Sell |
254,100
-2,000
| -0.8% | -$49.4K | 6.96% | 1 |
|
|
2019
Q1 | $6.7M | Hold |
256,100
| – | – | 6.96% | 1 |
|
|
2018
Q4 | $5.9M | Sell |
256,100
-1,100
| -0.4% | -$24.4K | 6.73% | 1 |
|
|
2018
Q3 | $6.06M | Hold |
257,200
| – | – | 5.81% | 1 |
|
|
2018
Q2 | $5.93M | Hold |
257,200
| – | – | 5.7% | 1 |
|
|
2018
Q1 | $6.33M | Sell |
257,200
-1,000
| -0.4% | -$26.3K | 6.33% | 1 |
|
|
2017
Q4 | $6.93M | Buy |
+258,200
| New | +$6.57M | 6.24% | 1 |
|
|
2016
Q3 | $5.54M | Buy |
266,200
+3,800
| +1% | +$94.2K | 5.97% | 1 |
|
|
2016
Q2 | $7.06M | Buy |
262,400
+400
| +0.2% | +$11K | 7.78% | 1 |
|
|
2016
Q1 | $7.1M | Hold |
262,000
| – | – | 7.82% | 1 |
|
|
2015
Q4 | $7.61M | Hold |
262,000
| – | – | 7.8% | 1 |
|
|
2015
Q3 | $7.1M | Hold |
262,000
| – | – | 7.52% | 1 |
|
|
2015
Q2 | $7.17M | Sell |
262,000
-1,800
| -0.7% | -$50.6K | 6.81% | 1 |
|
|
2015
Q1 | $7.04M | Buy |
263,800
+800
| +0.3% | +$18.4K | 6.26% | 1 |
|
|
2014
Q4 | $5.56M | Buy |
263,000
+9,000
| +4% | +$201K | 5.02% | 1 |
|
|
2014
Q3 | $6.05M | Hold |
254,000
| – | – | 5.58% | 1 |
|
|
2014
Q2 | $5.87M | Hold |
254,000
| – | – | 5.18% | 1 |
|
|
2014
Q1 | $5.8M | Hold |
254,000
| – | – | 5.48% | 1 |
|
|
2013
Q4 | $4.69M | Buy |
+254,000
| New | +$4.43M | 4.55% | 1 |
|
Other funds holding NVO
GA
VFM
ERP
OFA
Penbrook Management's NVO Position: Q3 2026 in Review
Penbrook Management reduced its Novo Nordisk (NVO) stake by 1.5% in Q3 2026, selling an estimated $217K and leaving 311,500 shares worth $11.8M. The position accounts for 6.97% of the portfolio, ranked #3.
Penbrook Management first reported a position in NVO in Q4 2013 and has held it in 48 quarters since. The position peaked at $44.6M in Q2 2024. 225 funds tracked by Wall St. Rank hold NVO as of Q3 2026.
- Penbrook Management held 311,500 shares of Novo Nordisk worth $11.8M as of Q3 2026.
- Penbrook Management sold 4,700 Novo Nordisk shares in Q3 2026, an estimated $217K.
- Novo Nordisk made up 6.97% of Penbrook Management's portfolio in Q3 2026, its #3 holding.
- Penbrook Management first reported a position in Novo Nordisk in Q4 2013 and has held it in 48 quarters since.
- Penbrook Management's Novo Nordisk position peaked at $44.6M in Q2 2024.
- 225 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.
Based on Penbrook Management's 13F filing for Q3 2026, filed 16 Oct 2026.